Effects of iodinated contrast agents on renal oxygenation level determined by blood oxygenation level dependent magnetic resonance imaging in rabbit models of type 1 and type 2 diabetic nephropathy

BMC Nephrology

Ke Xu²  Hong-shan Zhong²  Li Zhao¹  Wen-ge Sun¹  Ke Ren²  Jia-huan Wang² 

[1] Department of Radiology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, People’s Republic of China;Key Laboratory of Imaging Diagnosis and Interventional Radiology of Liaoning Province, Shenyang, Liaoning 110001, People’s Republic of China

关键词: Pimonidazole;    Rabbit;    Iodinated contrast agent;    Diabetic nephropathy;    Blood oxygenation level dependent magnetic resonance imaging;   

Others  :  1082633
DOI  :  10.1186/1471-2369-15-140

 received in 2014-06-18, accepted in 2014-08-29,  发布年份 2014

【 摘 要 】

Background

To evaluate the effects of contrast agents containing increasing concentrations of iodine on the renal oxygenation level determined by blood oxygenation level dependent (BOLD) magnetic resonance imaging (MRI) in a rabbit model of diabetic nephropathy.

Methods

BOLD-MRI was performed using saline or iodinated (I) contrast agents (200, 240, 300, 350 and 400 mg I/mL) at 1, 24, 48, and 72 h after experimentally inducing type 2 diabetic nephropathy in rabbits. Differences in renal oxygenation levels between type 1 and type 2 diabetic nephropathy were also assessed by BOLD-MRI after injecting 400 mg I/mL of contrast agent.

Results

Contrast agents increased the R2* values of the renal cortex, outer medulla, and inner medulla to the maximum levels at 24 h. The R2* values then decreased to their lowest levels at 72 h. The R2* was highest following injection of 400 mg I/mL, especially in the outer medulla. The R2* values were not significantly different between types 1 and 2 diabetic nephropathy.

Conclusions

Iodinated contrast agents had the greatest influence on renal outer medulla oxygenation level at 24 h in type 2 diabetic nephropathy, with the greatest effects observed at the 400 mg I/mL dose level. There were no differences in BOLD-MRI values between type 1 and type 2 diabetic nephropathy after administering the contrast agent at 400 mg I/mL.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Farag YM, Gaballa MR: Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant 2011, 26:28-35.
• [2]Schernthaner G, Schernthaner GH: Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. J Nephrol 2013, 26:975-985.
• [3]Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008, 74:867-872.
• [4]Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb M, Shina A, Zibertrest F, Eckardt KU, Rosen S, Heyman SN: Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008, 73:34-42.
• [5]Sodhi CP, Phadke SA, Batlle D, Sahai A: Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol 2001, 280:667-674.
• [6]Pakfetrat M, Nikoo MH, Malekmakanl , Tabande M, Roozbeh J, Reisjalali G, Zare N, Khajedehi P: Risk factors for contrast-related acute kidney injury according to risk, injury, failure, loss, and end-stage criteria in patients with coronary interventions. Iran J Kidney Dis 2010, 4:116-122.
• [7]Toprak O, Cirit M: Risk factors for contrast-induced nephropathy. Kidney Blood Press Res 2006, 29:84-93.
• [8]Meschi M, Detrenis S, Musini S, Strada E, Savazzi G: Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 2006, 34:2060. Med M
• [9]de Freitas do Carmo LP, Macedo E: Contrast-induced nephropathy: attributable incidence and potential harm. Crit Care 2012, 16:127. BioMed Central Full Text
• [10]Warner L, Glockner JF, Woollard J, Textor SC, Romero JC, Lerman LO: Determinations of renal cortical and medullary oxygenation using blood oxygen level-dependent magnetic resonance imaging and selective diuretics. Invest Radiol 2011, 46:41-47.
• [11]Hofmann L, Simon-Zoula S, Nowak A, Giger A, Vock P, Boesch C, Frey FJ, Vogt B: BOLD-MRI for the assessment of renal oxygenation in humans: acute effect of nephrotoxic xenobiotics. Kidney Int 2006, 70:144-150.
• [12]Poser BA, Norris DG: Fast spin echo sequences for BOLD functional MRI. MAGMA 2007, 20:11-17.
• [13]Prasad PV: Evaluation of intra-renal oxygenation by BOLD MRI. Nephron Clin Pract 2006, 103:c58-c65.
• [14]Ries M, Basseau F, Tyndal B, Jones R, Deminière C, Catargi B, Combe C, Moonen CW, Grenier N: Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging 2003, 17:104-113.
• [15]Lu Z, Lin Y, Shao H: Triglyceride as an optimal index of serum lipids predictor of insulin resistance in normoglycemic subjects. Chin J Pract Intern Med 2005, 25:512-513.
• [16]Haneder S, Augustin J, Jost G, Pietsch H, Lengsfeld P, Krämer BK, Schoenberg SO, Meyer M, Attenberger UI, Michaely HJ: Impact of iso- and low-osmolar iodinated contrast agents on BOLD and diffusion MRI in swine kidneys. Invest Radiol 2012, 47:299-305.
• [17]Prasad P, Li LP, Halter S, Cabray J, Ye M, Batlle D: Evaluation of renal hypoxia in diabetic mice by BOLD MRI. Invest Radiol 2010, 45:819-822.
• [18]O’Connor PM: Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol 2006, 33:9616olll.
• [19]Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, Watanabe Y, Takenaka T, Katayama S, Tanaka J, Suzuki H: Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 2011, 22:1429-1434.
• [20]Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO: Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003, 46:1153-1160.
• [21]Baines A, Ho P: Glucose stimulates O2 consumption, NOS, and Na/H exchange in diabetic rat proximal tubules. Am J Physiol Renal Physiol 2002, 283:F286-F293.
• [22]Dos Santos EA, Li LP, Ji L, Prasad PV: Early changes with diabetes in renal medullary hemodynamics as evaluated by fiberoptic probes and BOLD magnetic resonance imaging. Invest Radiol 2007, 42:157-162.
• [23]Yin WJ, Liu F, Li XM, Yang L, Zhao S, Huang ZX, Huang YQ, Liu RB: Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol 2012, 81:1426-1431.
• [24]Palm F: Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin Exp Pharmacol Physiol 2006, 33:9976olll.
• [25]Pollock JS, Carmines PK: Diabetic nephropathy: nitric oxide and renal medullary hypoxia. Am J Physiol Renal Physiol 2008, 294:F28-F29.
• [26]Stratta P, Quaglia M, Airoldi A, Aime S: Structure-function relationships of iodinated contrast media and risk of nephrotoxicity. Curr Med Chem 2012, 19:736-743.
• [27]Jost G, Pietsch H, Lengsfeld P, Hütter J, Sieber M: The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol 2010, 45:255-261.
• [28]Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, Möckel M, Persson PB: Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol 2007, 18:2912ollr0.
• [29]Bentata Y, Haddiya I, Latrech H, Serraj K, Abouqal R: Progression of diabetic nephropathy, risk of end-stage renal disease and mortality in patients with type-1diabetes. Saudi J Kidney Dis Transpl 2013, 24:392-402.
• [30]Perkins BA, Rabbani N, Weston A, Ficociello LH, Adaikalakoteswari A, Niewczas M, Warram J, Krolewski AS, Thornalley P: Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One 2012, 7:e35655.
• [31]Hirst JA, Taylor KS, Stevens RJ, Blacklock CL, Roberts NW, Pugh CW, Farmer AJ: The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012, 81:674-683.
• [32]Futrakul N, Butthep P, Vongthavarawat V, Futrakul P, Sirisalipoch S, Chaivatanarat T, Suwanwalaikorn S: Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy. Clin Hemorheol Microcirc 2006, 34:373-381.
• [33]Hasslacher C, Ritz E, Wahl P, Michael C: Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989, 4:859-863.
• [34]Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, Yamada H, Muto K, Uchigata Y, Ohashi Y, Iwamoto Y: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000, 58:302-311.